All individual trials at BioMed Valley Discoveries, Inc

An AllTrials project

All individual trials at BioMed Valley Discoveries, Inc

2 out of 3

66.7%

$2,383,214

$0

Status	Sponsor	Trial ID	Title	Completion date	Days overdue
reported-late	BioMed Valley Discoveries, Inc	NCT02296242	Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes [pACT]	2017-06-15	13
reported-late	BioMed Valley Discoveries, Inc	NCT01781429	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies [pACT]	2018-02-28	229
overdue	BioMed Valley Discoveries, Inc	NCT04488003	A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations	2023-01-03	37
ongoing	BioMed Valley Discoveries, Inc	NCT05221320	A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ)	2024-12-06

Download this data